Germany
Japan
United Kingdom
China
Research Areas
Download
USD 420.00
4 Weeks
CRYGD mouse monoclonal antibody,clone OTI4C1
| Applications | WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
CRYGD mouse monoclonal antibody,clone OTI6E11
| Applications | WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
CRYGD mouse monoclonal antibody,clone OTI7E10
| Applications | WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
USD 420.00
4 Weeks
USD 420.00
4 Weeks
MAP3K13 mouse monoclonal antibody,clone OTI5A2
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HLA-DQA2 mouse monoclonal antibody,clone OTI3E6
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
HLA-DQA2 mouse monoclonal antibody,clone OTI4C9
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 420.00
4 Weeks
SRC mouse monoclonal antibody,clone OTI6B2
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Active filters
Category
- Antibodies
Clonalities
- Monoclonal
Filter by
Target Symbol
- IL6 (134)
- CD4 (128)
- PECAM1 (111)
- IL1RL1 (102)
- PTPRC (90)
- CD99 (85)
- PDCD1 (84)
- CD19 (81)
- LGALS3 (79)
- KIT (71)
- CD68 (70)
- CD5 (66)
- MS4A1 (65)
- CD34 (62)
- NCAM1 (61)
- TNFRSF8 (53)
- CR2 (46)
- WNT3 (45)
- CD274 (42)
- CD2 (41)
- ESR1 (40)
- MME (40)
- CD22 (37)
- FCER2 (37)
- DVL2 (36)
- IL1RN (36)
- MAPK8 (36)
- TYRO3 (36)
- CD8A (35)
- CRP (35)
- IL2RA (33)
- CD33 (32)
- ANAPC11 (31)
- ROR2 (31)
- ANAPC2 (30)
- CD14 (29)
- CD79B (28)
- IL3RA (27)
- MAPK9 (27)
- TNF (25)
- CD3E (23)
- CSF3 (23)
- ANPEP (20)
- FCGR1A (17)
- CD74 (16)
- MAPK10 (15)
- PTK7 (15)
- RORA (15)
- POSTN (14)
- IL6R (13)
- ITGB3 (13)
- IL2 (12)
- CD7 (11)
- CD79A (11)
- IL36G (10)
- AGTPBP1 (9)
- ITGA2B (9)
- IL12B (8)
- IL1A (8)
- IL6ST (8)
- ROR1 (8)
- CD1A (7)
- FCGR3A (7)
- TLR8 (7)
- CALR (5)
- ESR2 (5)
- HLA-DRB5 (5)
- IL18 (5)
- IL6RA (5)
- LEF1 (5)
- TOLLIP (5)
- WNT3A (5)
- CD163 (4)
- HLA-A (4)
- IL10 (4)
- IL1B (4)
- IL36A (4)
- CRYGD (3)
- CXCL8 (3)
- ITGAX (3)
- CD46 (2)
- FUT4 (2)
- HLA CLASS II (2)
- HLA-DQA2 (2)
- HLA-G (2)
- TLR2 (2)
- TLR3 (2)
- TMED1 (2)
- WNT5B (2)
- ANAPC5 (1)
- ARAF (1)
- BRAF (1)
- CASP1 (1)
- CD10 (1)
- CD207 (1)
- CD30 (1)
- CD3D (1)
- CD3G (1)
- CDC42SE2 (1)
- CKMT2 (1)
Reactivities
Applications
Antibody Hosts
Isotypes
Conjugates
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (11)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (6)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (2222)
- Transmembrane (1753)
- ES Cell Differentiation/IPS (812)
- Secreted Protein (623)
- Adult stem cells (315)
- Protein Kinase (251)
- Embryonic stem cells (158)
- Induced pluripotent stem cells (118)
- Stem cell - Pluripotency (118)
- Phosphatase (88)
- Transcription Factors (86)
- Cancer stem cells (65)
- Protease (64)
- Nuclear Hormone Receptor (58)
- Stem cell relevant signaling - Wnt Signaling pathway (6)
- Stem cell relevant signaling - JAK/STAT signaling pathway (1)
Pathways
- Hematopoietic cell lineage (1036)
- Cell adhesion molecules (CAMs) (752)
- T cell receptor signaling pathway (395)
- Cytokine-cytokine receptor interaction (388)
- Pathways in cancer (379)
- Primary immunodeficiency (334)
- Toll-like receptor signaling pathway (289)
- Jak-STAT signaling pathway (240)
- NOD-like receptor signaling pathway (232)
- Prion diseases (202)
- Leukocyte transendothelial migration (197)
- B cell receptor signaling pathway (195)
- Graft-versus-host disease (181)
- Antigen processing and presentation (172)
- Wnt signaling pathway (169)
- Melanogenesis (163)
- Hypertrophic cardiomyopathy (HCM) (161)
- MAPK signaling pathway (142)
- Progesterone-mediated oocyte maturation (142)
- Cytosolic DNA-sensing pathway (137)
- Colorectal cancer (119)
- Fc gamma R-mediated phagocytosis (111)
- RIG-I-like receptor signaling pathway (105)
- Endocytosis (100)
- Fc epsilon RI signaling pathway (98)
- Focal adhesion (96)
- Adipocytokine signaling pathway (94)
- Type II diabetes mellitus (94)
- Basal cell carcinoma (92)
- ErbB signaling pathway (85)
- Neurotrophin signaling pathway (83)
- Insulin signaling pathway (82)
- Acute myeloid leukemia (81)
- Epithelial cell signaling in Helicobacter pylori infection (81)
- GnRH signaling pathway (80)
- Pancreatic cancer (79)
- Lysosome (69)
- Oocyte meiosis (63)
- Cell cycle (62)
- Ubiquitin mediated proteolysis (62)
- Type I diabetes mellitus (58)
- Alzheimer's disease (55)
- Renin-angiotensin system (54)
- Regulation of actin cytoskeleton (53)
- Hedgehog signaling pathway (52)
- Apoptosis (51)
- Allograft rejection (49)
- Complement and coagulation cascades (47)
- Systemic lupus erythematosus (46)
- Notch signaling pathway (35)
- Natural killer cell mediated cytotoxicity (33)
- Pathogenic Escherichia coli infection (33)
- Dilated cardiomyopathy (30)
- Asthma (26)
- Autoimmune thyroid disease (25)
- Metabolic pathways (20)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (19)
- Glutathione metabolism (19)
- Amyotrophic lateral sclerosis (ALS) (18)
- TGF-beta signaling pathway (17)
- ECM-receptor interaction (13)
- Viral myocarditis (13)
- Chemokine signaling pathway (10)
- Endometrial cancer (10)
- Prostate cancer (10)
- Adherens junction (8)
- Thyroid cancer (7)
- Bladder cancer (6)
- Chronic myeloid leukemia (6)
- Glioma (6)
- Renal cell carcinoma (6)
- Non-small cell lung cancer (5)
- VEGF signaling pathway (5)
- Vascular smooth muscle contraction (5)
- Long-term potentiation (4)
- Melanoma (4)
- mTOR signaling pathway (4)
- Axon guidance (3)
- Gap junction (3)
- Long-term depression (3)
- Small cell lung cancer (3)
- Tight junction (3)
- Arginine and proline metabolism (1)
- Dorso-ventral axis formation (1)
- Inositol phosphate metabolism (1)
- Phosphatidylinositol signaling system (1)
- Vibrio cholerae infection (1)